Dysmyelopoietic syndromes a search for prognostic factors in 193 patients

• Published in: Cancer Vol. 52; no. 1; pp. 83 - 90
• Main Authors: Coiffier, Bertrand, Adeleine, Patrice, Viala, Jean J., Bryon, Paul A., Fière, Denis, Gentilhomme, Odile, Vuvan, Huan
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 01.07.1983
• Subjects: Anemia, Sideroblastic - complications; Blood Platelets - pathology; Bone Marrow - pathology; Female; Humans; Male; Myeloproliferative Disorders - blood; Neutropenia - complications; Prognosis; Retrospective Studies; Splenomegaly - complications; Thrombocytopenia - complications
• DOI: 10.1002/1097-0142(19830701)52:1<83::AID-CNCR2820520117>3.0.CO;2-9
• ISSN: 0008-543X

Dysmyelopoietic syndromes cover sideroblastic or nonsideroblastic refractory anemia with or without excess of blasts, subacute or chronic myelomonocytic leukemia. The evolution of 193 patients was studied with regard to the initial hematologic picture. A certain number of variables of prognostic value have then been isolated: excess of marrow blasts (more than 5%); presence of circulating blasts or karyotypic anomalies; reduction in the number of polymorphonuclear leukocytes (less than 1.043 109/1), of monocytes (less than 0.136 109/1), of platelets (less than 140 109/1), of in vitro granulopoietic progenitors (less than 5 per 105 nucleated cells plated), of erythrocytic incorporation of 59Fe at day 14 (less than 12%), of hemoglobin level (less than 92 g/l); previous exposure to radiation or chemotherapy; early hemolysis in 51Cr‐labeled erythrocytes study; marrow heterogeneity in histology; less than 20% of ringed sideroblasts. The correlation between these variables and adjustements related to the length of survival and the order of magnitude of the critical level of the log‐rank test show that the most significant variables in descending order are: excess of marrow blasts, neutropenia, thrombopenia, presence of circulating blasts, the type of erythropoietic insufficiency, and decrease of in vitro growth. Cancer 52:83‐90, 1983.